Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].
Launay-Vacher V, Janus N, Beuzeboc P, Daniel C, Ray-Coquard I, Selle F, Rey JB, Jouannaud C, Spano JP, Thery JC, Morere JF, Goldwasser F, Mir O, Oudard S, Scotté F, Dorent R, Ludwig L, Deray G, Gligorov J. Launay-Vacher V, et al. Among authors: thery jc. Bull Cancer. 2015 Nov;102(11):906-14. doi: 10.1016/j.bulcan.2015.09.001. Bull Cancer. 2015. PMID: 26603517 French.
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.
Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP. Hollebecque A, et al. Among authors: thery jc. Eur J Cancer. 2017 Aug;81:81-89. doi: 10.1016/j.ejca.2017.05.021. Epub 2017 Jun 12. Eur J Cancer. 2017. PMID: 28618305 Clinical Trial.
Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
Sefrioui D, Perdrix A, Sarafan-Vasseur N, Dolfus C, Dujon A, Picquenot JM, Delacour J, Cornic M, Bohers E, Leheurteur M, Rigal O, Tennevet I, Thery JC, Alexandru C, Guillemet C, Moldovan C, Veyret C, Frebourg T, Di Fiore F, Clatot F. Sefrioui D, et al. Among authors: thery jc. Int J Cancer. 2015 Nov 15;137(10):2513-9. doi: 10.1002/ijc.29612. Epub 2015 Jun 11. Int J Cancer. 2015. PMID: 25994408
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
Clatot F, Perdrix A, Augusto L, Beaussire L, Delacour J, Calbrix C, Sefrioui D, Viailly PJ, Bubenheim M, Moldovan C, Alexandru C, Tennevet I, Rigal O, Guillemet C, Leheurteur M, Gouérant S, Petrau C, Théry JC, Picquenot JM, Veyret C, Frébourg T, Jardin F, Sarafan-Vasseur N, Di Fiore F. Clatot F, et al. Among authors: thery jc. Oncotarget. 2016 Nov 15;7(46):74448-74459. doi: 10.18632/oncotarget.12950. Oncotarget. 2016. PMID: 27801670 Free PMC article.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378).
Tryfonidis K, Basaran G, Bogaerts J, Debled M, Dirix L, Thery JC, Tjan-Heijnen VC, Van den Weyngaert D, Cufer T, Piccart M, Cameron D; EORTC-Breast Cancer Group. Tryfonidis K, et al. Among authors: thery jc. Eur J Cancer. 2016 Jan;53:144-54. doi: 10.1016/j.ejca.2015.10.012. Epub 2015 Dec 24. Eur J Cancer. 2016. PMID: 26724641 Clinical Trial.
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
Dalenc F, Lusque A, De La Motte Rouge T, Pistilli B, Brain E, Pasquier D, Debled M, Thery JC, Gonçalves A, Desmoulins I, Levy C, Uwer L, Ferrero JM, Eymard JC, Mouret-Reynier MA, Patsouris A, Frenel JS, Petit T, Chevrot M, Bachelot T, Guiu S. Dalenc F, et al. Among authors: thery jc. Eur J Cancer. 2022 Mar;164:70-79. doi: 10.1016/j.ejca.2021.12.031. Epub 2022 Feb 14. Eur J Cancer. 2022. PMID: 35176614
Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer.
Clatot F, Fontanilles M, Lefebvre L, Lequesne J, Veyret C, Alexandru C, Leheurteur M, Guillemet C, Gouérant S, Petrau C, Théry JC, Rigal O, Moldovan C, Tennevet I, Rastelli O, Poullain A, Savary L, Bubenheim M, Georgescu D, Gouérant J, Gilles-Baray M, Di Fiore F. Clatot F, et al. Among authors: thery jc. Eur J Cancer. 2020 Feb;126:116-124. doi: 10.1016/j.ejca.2019.11.022. Epub 2020 Jan 10. Eur J Cancer. 2020. PMID: 31931269 Clinical Trial.
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M, Lacroix-Triki M, Garrabey J, Boursin Y, Deloger M, Fu Y, Commo F, Scott V, Lacroix L, Dieci MV, Kamal M, Diéras V, Gonçalves A, Ferrerro JM, Romieu G, Vanlemmens L, Mouret Reynier MA, Théry JC, Le Du F, Guiu S, Dalenc F, Clapisson G, Bonnefoi H, Jimenez M, Le Tourneau C, André F. Lefebvre C, et al. Among authors: thery jc. PLoS Med. 2016 Dec 27;13(12):e1002201. doi: 10.1371/journal.pmed.1002201. eCollection 2016 Dec. PLoS Med. 2016. PMID: 28027327 Free PMC article.
32 results